Antithrombin replacement in patients with sepsis and septic shock

Haematologica

Volumn 84, Issue 5, 1999, Pages 452-460

  Giudici, Daniela ^a   Baudo, Francesco ^b   Palareti, Gualtiero ^c   Ravizza, Adriano ^b   Ridolfi, Lorenza ^c   D'Angelo, Armando ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antithrombin replacement therapy; Diffuse intravascular fibrin formation; Protein C; Sepsis; Septic shock

Indexed keywords

ANTITHROMBIN;

ANTICOAGULANT THERAPY; ARTICLE; ASSISTED VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MULTIPLE ORGAN FAILURE; SEPSIS; SEPTIC SHOCK; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 0032874830     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Parrillo JE, Parker MM, Natanson C, et al. Septic shock: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-42.
2. Manship L, McMlllin RD, Brown JJ. The influence of sepsis and multisystem and organ failure on mortality in the surgical intensive care unit. Am Surg 1984; 50:94-101.
3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-55.
4. Tilney NL, Bailey GL, Morgan AP, et al. Sequential system failure after rupture of abdominal aortic aneurysms. Ann Surg 1973; 178:117-21.
5. Baue AE. Multiple, progressive or sequential systems failure: a syndrome of the 1970s. Arch Surg 1975; 110:779-86.
6. Fahey III TJ, Tracey KJ. Cytokines, tumor necrosis factor and other mediators of sepsis. In: Carlson RW, Geheb MA, eds. Principles & Practice of Medical Intensive Care. Philadelphia, WB Saunders Company; 1993. p. 311-22.
7. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation 1986; 73:637-44.
8. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75:533-41.
9. Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombohemorrhagic disorders. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia, JB Lippincott Company, 1994. p. 1023-63.
10. Dixon AC, Parrillo JE. Cardiovascular dysfunction in septic shock. In: Carlson RW, Geheb MA, eds. Principles and Practice of Medical Intensive Care. Philadelphia: WB Saunders Co.; 1993. p. 323-40.
11. Lefer AM, Martin J. Origin of the myocardial depressant factor in shock. Am J Physiol 1970; 218:1423-9.
12. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 1985; 76:1539-53.
13. Hansen-Flaschen JH. Adult respiratory distress syndrome. In: Carlson RW, Geheb MA, eds. Principles and Practice of Medical Intensive Care. Philadelphia: WB Saunders Co.; 1993. p. 816-26.
14. Kaplan RL, Sahn SA, Petty TL. Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis. Arch Intern Med 1979; 139:867-9.
15. Sibbald WJ, Darrah WC. Multiple organ system failure in sepsis. In: Carlson RW, Geheb MA, eds. Principles and Practice of Medical Intensive Care. Philadelphia: WB Saunders Co.; 1993. p. 340-52.
16. Solomon MA, Natanson C. Treatment of sepsis and septic shock. In: Carlson RW, Geheb MA, eds, Principles and Practice of Medical Intensive Care. Philadelphia: WB Saunders Co.; 1993. p. 365-80.
17. Salvo I, DeCian W, Musicco M, et al. The Italian SEP-SIS study: preliminary results on incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Int Care Med 1995; 21:5244-9.
18. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia Coli. N Engl J Med 1982; 307:1225-30.
19. Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double blind, placebo-controlled trial. N Engl J Med 1991; 324:429-36.
20. Beutler B, Milsark IW, Cerami AC, Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-71.
21. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330:662-4.
22. Hinshaw LB, Tekamp-Olson P, Chang ACK, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ Shock 1990; 30:279-88.
23. Coalson JJ, Benjamin B, Archer LT, et al. Prolonged shock in the baboon subjected to infusion of E. Coli endotoxin. Circ Shock 1978; 5:423-37.
24. Taylor FB Jr, Chang ACK, Peer GT, et al. DEGR-Factor Xa blocks disseminated intravascular coagulation initiated by Escherichia Coli without preventing shock or organ damage. Blood 1991; 78:364-8.
25. Warr TA, Rao VM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-9.
26. Triantaphyllopoulos DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemost 1984; 51: 232-5.
27. Taylor FB Jr, Emerson TE Jr, Jordan R, Chang A, Blick KE. Antithrombin III prevents the lethal effects of Escherichia Coli infusion in baboons. Circ Shock 1988; 26:227-35.
28. Taylor FB Jr., Chang A, Esmon CT, D'Angelo A, Viganò D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. Coli infusion in the baboon. J Clin Invest 1987; 79:918-25.
29. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr., Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia Coli septic shock. J Clin Invest 1993; 91:2850-6.
30. Buller HR, Ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications and treatment with antithrombin III concentrate. Am J Med 1989; 87(suppl 3B):44s-8s.
31. Blauhut, B, Necek S, Vinazzer H, Bergmann H. Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 1982; 27:271-8.
32. Hesselvik JF, Malm J, Dahlbäck B, Blomback M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991; 62:126-9.
33. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multi organ failure and disseminated intravascular coagulation. Compared pattern of ATIII, protein C, protein S deficiencies. Chest 1992; 101:816-23.
34. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1984; 39:81-9.
35. Wilson RF, Mammen EF, Robson MC, Heggers JP, Souiller G, DePoli PA. Antithrombin, prekallikrein and fibronectin levels in surgical patients. Arch Surg 1986; 121:635-43.
36. Sandset PM, Roise O, Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in post operative/ post traumatic septicemia: increased levels in fatal cases. Haemostasis 1989; 19:189-95.
37. Hesselvik JF, Blomback M, Brodin B, Maller R. Coagulation, fibrinolysis and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17:724-33.
38. Lammle B, Tran TM, Ritz R, Duckert F. Plasma prekallikrein, factor XII, ATIII, C1-inhibitor and α2 macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 1984; 82:396-404.
39. Maki M, Terao T, Ikenoue T, et al. Clinical evaluation of antithrombin concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Gynecol Obstet Invest 1987; 23:230-40.
40. Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost 1989; 15:347-52.
41. Palareti G, Legnani C, Ludovici S, et al. Studio preliminare per la valutazione di fattibilità di uno studio clinico policentrico per la valutazione dell'efficacia terapeutica di un concentrato di antitrombina III (Immuno) nella sindrome da coagulazione intravascolare. Haematologica 1990; 75:21-8.
42. Lechner K, Kyrle PA. Antithrombin III concentrates -Are they clinically useful? Thromb Haemost 1995; 73: 340-8.
43. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104:882-8.
44. th European Congress on Intensive Care Medicine, Glasgow, 1996. p. 385-90.
45. Harper PL, Williamson L, Park G, Smith JK, Carrell RW. A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfusion Med 1991; 1:121-8.
46. Albert J, Blomqvist H, Gardlund B, Jakobsson J, Svensson J, Blomback M. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 1992; 36:745-52.
47. Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double blind, randomized multicenter study. Int Care Med 1998; 24:336-42.
48. La Gall JR, Loirat P, Alperovith A, et al. A simplified acute physiology score for ICU patients. Crit Care Med 1984; 12:975-7.
49. Goris RJA, Boekhorst TP, Nuytinck JKS, Gimbrere JSF. Multiple organ failure. Arch Surg 1985; 120:1109-15.
50. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology 1987; 7:1346-58.
51. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88:881-6.
52. Smtih OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350:1590-3.
53. Fijnvandraat K, Derkx B, Peters M, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73:15-20.
54. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995; 5:141-8.